Madureira Adrienne, Bergeron Anne, Lacroix Claire, Robin Marie, Rocha Vanderson, de Latour Régis Peffault, Ferry Christèle, Devergie Agnès, Lapalu Jordane, Gluckmana Eliane, Socié Gérard, Ghannoum Mahmoud, Ribaud Patricia
Hematology-Bone Marrow Transplant Unit, Saint-Louis Hospital, Université Paris VII, 1 avenue Claude Vellefaux, 75010 Paris, France.
Int J Antimicrob Agents. 2007 Dec;30(6):551-4. doi: 10.1016/j.ijantimicag.2007.07.026.
During the period January 2004 to April 2007, nine cases of breakthrough invasive aspergillosis occurred among 156 allogeneic haematopoietic stem cell transplant recipients receiving caspofungin therapy, mainly for empirical treatment of persisting fever. Voriconazole salvage therapy induced two complete responses. However, seven patients ultimately died a median of 5 weeks after diagnosis, including five patients with aspergillosis. This high incidence of breakthrough invasive aspergillosis in this patient population receiving caspofungin therapy warrants further investigation.
在2004年1月至2007年4月期间，156名接受卡泊芬净治疗的异基因造血干细胞移植受者中发生了9例突破性侵袭性曲霉病，主要用于持续发热的经验性治疗。伏立康唑挽救治疗诱导了2例完全缓解。然而，7例患者最终在诊断后中位5周死亡，其中包括5例曲霉病患者。在接受卡泊芬净治疗的该患者群体中，突破性侵袭性曲霉病的高发病率值得进一步研究。
